Current Global Lung Cancer Screening Landscape
Alexander Roediger, Global Lead Oncology Policy at Merck & Co, Inc. and MSD discusses the current disease burden of lung cancer and the current landscape for lung cancer screening programs around the world. He also shares findings from his research that were presented at the IASLC 2022 World Conference on Lung Cancer (WCLC).
Alexander Roediger leads Oncology Policy at Merck & Co., Inc., Rahway, N.J., USA (known as MSD outside the U.S. and Canada) for Europe, Middle East, Africa and Canada (EMEAC). In his current role, he focuses on oncology policy issues, including health system financing, pricing and reimbursement and innovation policies. He has a Master’s degree in Philosophy from the University of Zurich and in 2006 he received his Executive Master’s Degree of Business Administration from the University of St. Gallen. Before joining Merck & Co., Inc., Rahway, N.J., USA, he worked for UNICEF Switzerland and Helsana Insurances.
